Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | AR | P10275 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3839373 | 0.91 | BACE1 (0.53) | MAPTHTTBACE1MAPK1ALDH1A1 | |
| SCHEMBL7193890 | 0.88 | HIF1A (0.49) | HIF1AARMEN1KMT2AMAPT | |
| SCHEMBL3834082 | 0.85 | HTR6 (0.51) | BACE1ALDH1A1POLBCTSLCTSS | |
| SCHEMBL7191787 | 0.83 | BACE1 (0.48) | MAPTBACE1ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL5134084 | 0.83 | BACE1 (0.57) | MAPTBACE1ALDH1A1MMP2MMP9 | |
| SCHEMBL5041194 | 0.83 | BACE1 (0.57) | MAPTBACE1ALDH1A1MMP2MMP9 | |
| SCHEMBL7193260 | 0.81 | BACE1 (0.46) | MAPTBACE1MMP2MMP9POLB | |
| SCHEMBL3834647 | 0.80 | ALDH1A1 (0.67) | HIF1AARMEN1KMT2AMAPT | |
| SCHEMBL3837363 | 0.77 | BACE1 (0.54) | MEN1KMT2AMAPTBACE1ALDH1A1 | |
| SCHEMBL7194146 | 0.76 | MMP2 (0.53) | MEN1KMT2AMAPTBACE1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1235595-B8 | INTEGRIN-MEDIATED DRUG TARGETING | BAYER SCHERING PHARMA AG (DE) | 2009-10-07 | — | — | EP | disclosed |
| US-7220824-B1 | Integrin-mediated drug targeting | BAYER AKTIENGESELLSCHAFT (DE) | 2007-05-22 | — | — | US | disclosed |
| US-20060189544-A1 | Integrin-Mediated drug targeting | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-24 | — | — | US | disclosed |
| US-6589972-B2 | Anticancer agents, osteoporosis, arteriosclerosis, restnosis,vision defects | BAYER AKTIENGESELLSCHAFT (DE) | 2003-07-08 | — | — | US | disclosed |
| EP-1235595-A2 | INTEGRIN-MEDIATED DRUG TARGETING | Bayer Aktiengesellschaft (DE) | 2002-09-04 | — | — | EP | disclosed |
| US-20010031788-A1 | Beta-phenylalanine derivatives as integrin antagonists | SCHOOP ANDREAS (DE) | 2001-10-18 | — | — | US | disclosed |
| US-6291503-B1 | β-phenylalanine derivatives as integrin antagonists | BAYER AKTIENGESELLSCHAFT (DE) | 2001-09-18 | — | — | US | disclosed |
| WO-2001017563-A2 | INTEGRIN-MEDIATED DRUG TARGETING | BAYER AKTIENGESELLSCHAFT (DE) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189544-A1 | Integrin-Mediated drug targeting | ITGAV, ITGB3, ITGB1 | HIF1A 2498/4885AR 2350/4885MEN1 2199/4885 |
| US-20010031788-A1 | Beta-phenylalanine derivatives as integrin antagonists | ITGB4, ITGA4, ITGB2 | HIF1A 1204/4885AR 326/4885MEN1 4639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.